4-butyl-5-chloromethyl-2-(4-trifluoromethyl-phenyl)-thiazole | 866531-18-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-butyl-5-chloromethyl-2-(4-trifluoromethyl-phenyl)-thiazole
• 英文别名: 4-butyl-5-(chloromethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole
• CAS: 866531-18-2
• 化学式: C₁₅H₁₅ClF₃NS
• 分子量: 333.805
• InChiKey: POZQHHUDJHZFBE-UHFFFAOYSA-N

物化性质

• 沸点：
  394.7±52.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-butyl-5-chloromethyl-2-(4-trifluoromethyl-phenyl)-thiazole 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 1-[4-butyl-2-(4-(trifluoromethyl)-phenyl)-thiazol-5-ylmethyl]-5-methoxy-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  [EN] 7-AZAINDOLES AND THEIR USE AS PPAR AGONISTS
  [FR] 7-AZAINDOLES ET LEUR UTILISATION EN TANT QU'AGONISTES DE PPAR

  摘要：

  这项发明涉及7-氮杂吲哚及其生理上可接受的盐和生理功能衍生物，显示PPAR激动剂活性。所描述的是具有式I的化合物，其中基团如所定义的，以及它们的生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的紊乱。

  公开号：

  WO2006029699A1
• 作为产物：
  描述：

  4-(三氟甲基)硫代苯甲酰胺 在 lithium aluminium tetrahydride 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 4-butyl-5-chloromethyl-2-(4-trifluoromethyl-phenyl)-thiazole
  参考文献：
  名称：

  Oxadiazolones, processes for their preparation and their use as pharmaceuticals

  摘要：

  公开号：

  EP1586573B1

文献信息

• Indole derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060166983A1

  公开（公告）日：2006-07-27

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in (I) are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过使用结构式(I)的化合物调节过氧化物酶体增殖物激活受体进行治疗的方法。式(I)中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为对治疗和预防X综合症、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化以及其他与X综合症和心血管疾病有关的疾病有效。
• Peroxisome proliferator activated receptor modulators
  申请人：Conner Eugene Scott

  公开号：US20060084663A1

  公开（公告）日：2006-04-20

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, substituted aryl(C 0 -C 4 )alkyl, substituted aryloxy(C 0 -C 4 )alkyl, substituted arylthio(C 0 -C 4 )alkyl, unsubstituted aryl(C 0 -C 4 )alkyl, unsubstituted aryloxy(C 0 -C 4 )alkyl, and unsubstituted arylthio(C 0 -C 4 )alkyl; (b) T1 is C or N; (c) Q is selected from the group consisting of O, a single bond, O(CH 2 ) q and C; (d) q is 1 or 2; (e) W is selected from the group consisting of O, S, (CH 2 ) r N(R20)(CH 2 ) k , NHSO 2 , C(O)N(R20)(CH 2 ) r , (CH 2 ) r N(R20)C(O), and SO 2 ; (f) X is C m H 2m ; (g) m is 0, 1 or 2; (h) A is an functional group selected from the group consisting of carboxyl, C1-C3 alkylnitrile, carboxamide, and (CH 2 ) n COOR19; and (i) R19 is selected from the group consisting of hydrogen, optionally substituted C1-C4alkyl and optionally substituted arylmethyl.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，式I：其中：(a) R5选自(C1-C6)烷基，(C1-C6)烯基，取代芳基(C0-C4)烷基，取代芳氧基(C0-C4)烷基，取代芳硫基(C0-C4)烷基，未取代芳基(C0-C4)烷基，未取代芳氧基(C0-C4)烷基和未取代芳硫基(C0-C4)烷基组成的群体；(b) T1为C或N；(c) Q选自O，单键，O(CH2)q和C的群体；(d) q为1或2；(e) W选自O，S，(CH2)rN(R20)(CH2)k，NHSO2，C(O)N(R20)(CH2)r，(CH2)rN(R20)C(O)和SO2的群体；(f) X为CmH2m；(g) m为0，1或2；(h) A为从羧基，C1-C3烷基腈，羧酰胺和(CH2)nCOOR19的群体中选取的一个功能基团；(i) R19选自氢，可选取代的C1-C4烷基和可选取代的芳基甲基的群体。
• Fused heterocyclic derivates as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060217374A1

  公开（公告）日：2006-09-28

  The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

  本发明涉及一种通过利用结构式（I）的化合物来调节过氧化物酶体增殖物激活受体进行治疗的方法。I中的变量在此定义。还包括化合物、制备化合物的方法和制药组合物。本发明的化合物被认为在治疗和预防综合征X、H型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉粥样硬化和其他与综合征X和心血管疾病相关的疾病方面具有疗效。
• 7-AZAINDOLES, PHARMACEUTICAL COMPOSITIONS AND THEIR THERAPEUTIC APPLICATIONS
  申请人：KEIL Stefanie

  公开号：US20070254908A1

  公开（公告）日：2007-11-01

  The present invention relates generally to compounds and compositions for the treatment of metabolic diseases and specifically, the present invention relates to compounds that therapeutically modulation and control lipid and/or carbohydrate metabolism and are thus suitable for the prevention and/or treatment of diseases such as type 2 diabetes, atherosclerosis, and the diverse manifestations thereof. The present invention relates to 7-azaindoles, their physiologically acceptable salts and functional derivatives thereof that exhibit a high degree of peroxisome proliferator-activated receptors (PPAR) agonist activity. Compounds of the present invention are described by formula I: in which the R-groups are herein defined, together with their pharmaceutically acceptable salts, therapeutic methods for their use and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及化合物和组合物，用于治疗代谢性疾病，特别是涉及治疗能够治疗和控制脂质和/或碳水化合物代谢的化合物，因此适用于预防和/或治疗2型糖尿病、动脉硬化及其不同表现形式等疾病。本发明涉及7-氮杂吲哚、其生理上可接受的盐和功能衍生物，它们表现出高度的过氧化物酶体增殖物激活受体（PPAR）激动剂活性。本发明的化合物由式I描述：其中R基在此定义，以及它们的药学上可接受的盐、治疗方法和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS
  申请人：KEIL Stefanie

  公开号：US20080255212A1

  公开（公告）日：2008-10-16

  The invention relates to oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing peroxisome proliferator activator receptor (PPAR) delta agonist activity comprising compounds of formula I, in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or de-myelinating disorders of the central and peripheral nervous systems and/or neurological diseases involving neuro-inflammatory processes and/or other peripheral neuropathies.

  本发明涉及氧化二氮杂环酮及其生理上可接受的盐和生理上功能衍生物，其显示过氧化物酶体增殖物激活受体（PPAR）δ激动剂活性，包括式I中的化合物，其中R1-R7取代基以及U、V、W、X、Y和z基团的定义如本文所述，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病；中枢神经系统和/或周围神经系统的神经退行性疾病和/或去髓鞘疾病以及涉及神经炎症过程和/或其他周围神经病的神经疾病。